According to GlobalData’s medical device pipeline database, 256 IVD Analyzers and Reagents devices are in various stages of development globally. GlobalData’s report IVD Analyzers and Reagents provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.

Smarter leaders trust GlobalData

Of these devices, 132 are in active development, while the remaining 128 are in an inactive stage of development. There are 75 products in the early stages of development, and the remaining 57 are in the late stages of development.

In Vitro Diagnostics (IVD) include reagents, instruments and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. In vitro diagnostic (IVD) analyzers and reagents are medical devices used to perform laboratory tests on human samples, such as blood, urine, and tissue. IVD analyzers are machines that automate the testing process, while IVD reagents are the chemicals and other materials used in the tests.

Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.

Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed IVD Analyzers and Reagents pipeline devices are all expected to be approved within the next ten years.

Currently, private organizations, public entities and institutions are working on the development of IVD Analyzers and Reagents devices. Overall, most of these IVD Analyzers and Reagents pipeline devices are being developed by private entities.

Key players involved in the active development of IVD Analyzers and Reagents include Roche Diagnostics, EKF Diagnostics, Rekom Biotech, Daxor, BreviTest Technologies, Center for Innovation in Point-of-Care Technologies for HIV/AIDS, GenapSys, Atonomics, Boditech Med and Newcastle University.

For a complete picture of the developmental pipeline for IVD Analyzers and Reagents devices, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.